Mangalam Drugs & Organics Ltd. (IN:MANGALAM)
:MANGALAM
Want to see IN:MANGALAM full AI Analyst Report?
Top Page
Mangalam Drugs & Organics Ltd.
(MANGALAM)
Select Model
Select Model
Rating:43Neutral
Price Target:
₹29.00
▼(-4.61% Downside)
Action:Reiterated
Date:05/17/26
The score is held down primarily by weak financial performance (FY2026 loss, negative operating/free cash flow, and higher leverage). Technicals are broadly neutral and do not indicate a strong reversal, while valuation is constrained by negative earnings and no dividend data.
Positive Factors
Niche B2B specialty chemicals
Mangalam operates in specialty pharmaceutical intermediates, a B2B segment with technical barriers and sticky customer relationships. This business model supports durable demand from drug makers and typically enables contract visibility, repeat orders, and relative pricing stability over months.
Negative Factors
Large FY2026 loss & margin deterioration
A material swing to large FY2026 losses and negative operating margins signals structural pressure on profitability. Sustained margin erosion limits internal reinvestment, weakens pricing leverage, and raises the bar for operational fixes needed to restore multi-quarter profitability and protect cash.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche B2B specialty chemicals
Mangalam operates in specialty pharmaceutical intermediates, a B2B segment with technical barriers and sticky customer relationships. This business model supports durable demand from drug makers and typically enables contract visibility, repeat orders, and relative pricing stability over months.
Read all positive factors
Mangalam Drugs & Organics Ltd. (MANGALAM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹480.86M
Dividend YieldN/A
Average Volume (3M)5.11K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue Growth-26.89%
EPS Growth-760.69%
CountryIN
Employees432
SectorBasic Materials
Sector Strength58
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-12.51
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.42
Price to Sales (P/S)0.19
P/FCF Ratio-2.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mangalam Drugs & Organics Ltd. Business Overview & Revenue Model
Company Description
Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for ...
How the Company Makes Money
The company primarily makes money by manufacturing and selling pharmaceutical intermediates/specialty organic chemicals to business customers (B2B). Revenue is generated from (1) sales of its core chemical/intermediate products (the main operating...
Mangalam Drugs & Organics Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
42
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.68B | 2.32B | 3.18B | 3.67B | 3.70B | 4.47B |
| Gross Profit | 1.03B | 232.46M | 1.50B | 188.12M | 287.77M | 546.89M |
| EBITDA | 112.23M | -149.03M | 363.25M | 174.95M | 259.54M | 451.84M |
| Net Income | -197.98M | -444.00M | 67.21M | -90.72M | 12.70M | 196.57M |
Balance Sheet | ||||||
| Total Assets | 3.17B | 3.15B | 3.66B | 3.34B | 3.60B | 3.28B |
| Cash, Cash Equivalents and Short-Term Investments | 96.75M | 7.01M | 25.89M | 11.87M | 26.88M | 19.55M |
| Total Debt | 949.21M | 1.05B | 962.30M | 1.07B | 885.47M | 879.04M |
| Total Liabilities | 1.89B | 2.12B | 2.17B | 1.98B | 2.08B | 1.78B |
| Stockholders Equity | 1.28B | 1.03B | 1.49B | 1.36B | 1.52B | 1.51B |
Cash Flow | ||||||
| Free Cash Flow | 19.14M | -208.11M | 223.93M | -79.20M | 116.09M | -19.60M |
| Operating Cash Flow | 77.10M | -89.12M | 425.94M | 39.13M | 395.23M | 257.09M |
| Investing Cash Flow | -57.59M | -117.25M | -194.72M | -118.27M | -221.72M | -273.26M |
| Financing Cash Flow | -11.63M | 187.49M | -217.12M | 52.27M | -166.17M | 29.79M |
Mangalam Drugs & Organics Ltd. Technical Analysis
Positive
30.40
Price Trends
30.10
Positive
32.21
Negative
48.97
Negative
Market Momentum
0.10
Negative
52.55
Neutral
38.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANGALAM, the sentiment is Positive. The current price of 30.4 is above the 20-day moving average (MA) of 29.63, above the 50-day MA of 30.10, and below the 200-day MA of 48.97, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 52.55 is Neutral, neither overbought nor oversold. The STOCH value of 38.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MANGALAM.
Mangalam Drugs & Organics Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹1.03B | 7.38 | ― | ― | 2.66% | -1.90% | |
63 Neutral | ₹736.41M | 21.33 | ― | ― | 15.04% | -11.75% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
56 Neutral | ₹524.34M | 172.45 | ― | ― | -27.51% | 356.89% | |
47 Neutral | ₹387.28M | -4.63 | ― | ― | -48.93% | -180.45% | |
43 Neutral | ₹480.86M | -0.97 | ― | ― | -26.89% | -760.69% | |
39 Underperform | ₹523.19M | -2.21 | ― | ― | -35.33% | -65.64% |
* Basic Materials Sector Average
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
29.85
-49.24
-62.26%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
32.13
-13.01
-28.82%
IN:LASA
Lasa Supergenerics Ltd.
8.00
-9.10
-53.22%
IN:PAR
Par Drugs and Chemicals Limited
85.50
-19.52
-18.59%
IN:VAISHALI
Vaishali Pharma Ltd.
6.97
-6.03
-46.38%
IN:VIVIMEDLAB
Vivimed Labs Limited
6.62
1.72
35.10%
Mangalam Drugs & Organics Ltd. Corporate Events
Mangalam Drugs & Organics Closes Trading Window Ahead of FY26 Results
Mar 24, 2026
Mangalam Drugs Organics Ltd. has announced the closure of its trading window for designated persons and their immediate relatives from April 1, 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s int...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.